← All trials
NCT04501978
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 4, 2020
- Primary completion
- Jul 31, 2022
- Completion date
- Jul 31, 2022
- First posted
- Aug 6, 2020
- Last posted
- Jan 5, 2021
- Enrollment
- 10000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- Eli LillyCollaborator
- Department of Veteran AffairsCollaborator
- GlaxoSmithKlineCollaborator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- University of New South WalesCollaborator
- University of CopenhagenCollaborator
- Medical Research CouncilCollaborator
- Vir Biotechnology, Inc.Collaborator
- Brii BiosciencesCollaborator
- University of CopenhagenOverall official - principal investigator
- University of MinnesotaStudy chair
- International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.